OBJECTIVE: To explore the impact of @entity1104 ( @entity1104 ) to minimal but gross @entity66 ( @entity66 ) in @entity1 with bulky stage IIIC @entity2670 , or primary @entity3906 . METHODS: We retrospectively reviewed all @entity1 with the aforementioned diagnosis who underwent @entity1104 at our institution from 01/2001-12/2010. Those with disease of non-epithelial histology or borderline @entity5 were excluded. Clinicopathologic data were abstracted, and appropriate statistical tests were used. RESULTS: We identified 496 eligible @entity1 . Median age was 62years; 91% had disease of serous histology. @entity1 were grouped by @entity66 status: no gross @entity66 , 184 (37%); @entity66 of 1-5mm, 127 (26%); @entity66 of 6-10mm, 54 (11%); and @entity66 >10mm, 131 (26%). With a median follow-up of 53months, the median progression-free survivals (PFS) were: 26.7, 20.7, 16.2, and 13.6months, respectively (p<0.001). The median @entity1349 ( @entity1349 ) were 83.4, 54.5, 43.8, and 38.9months, respectively (p<0.001). Among @entity1 with @entity66 following @entity1104 , those with @entity66 of 1-10mm had improved PFS (p<0.001) and @entity1349 (p=0.001) compared with those with @entity66 >10mm. @entity1 with @entity66 1-10mm who received intravenous/intraperitoneal (IV/IP) chemotherapy were younger and had prolonged @entity1349 compared with those solely exposed to IV chemotherapy (p<0.001 and p=0.002, respectively). CONCLUSIONS: @entity1104 to no gross @entity66 was associated with the longest PFS and @entity1349 . However, cytoreduction to 1-10mm of @entity66 was also associated with better survival outcomes compared with cytoreduction to >10mm of @entity66 . We conclude that @entity1104 remains an appropriate option for @entity1 with a high likelihood of achieving @entity66 1-10mm, especially for younger @entity1 who can receive IV/IP chemotherapy after @entity1104 .

Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at XXXX or neoadjuvant chemotherapy?

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease', 'RD'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity3906 :: ('MESH:D010534', 'Disease') :: ['peritoneal cancer'] @entity2670 :: ('MESH:D010049', 'Disease') :: ['ovarian, fallopian tube'] @entity1104 :: ('MESH:D000267', 'Disease') :: ['PDS', 'primary debulking surgery'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survivals']
@entity1104 :: (MESH:D000267,Disease) :: ['primary debulking surgery']
